Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood protein reveal hidden heart risks in sleep apnea?

NCT ID NCT07829809

NEW Knowledge-focused Sponsor: Aswan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are studying whether a blood protein called adropin can signal blood vessel damage and disease severity in obese adults with obstructive sleep apnea. The trial compares adropin levels in obese patients with and without the sleep disorder, and checks how those levels relate to breathing pauses during sleep and to a marker of vessel dysfunction called endothelin-1. About 80 adults aged 20 to 75 provide fasting blood samples after a sleep study. The goal is to see whether adropin could serve as an early warning sign for cardiovascular problems in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a blood test for adropin, a protein measured in fasting blood samples
What this could lead to
If adropin tracks with blood vessel damage in sleep apnea, doctors could one day use a simple blood test to spot heart and vessel risks earlier in obese patients with the condition.
What could go wrong
This is a small observational study of 80 people at a single center, so it can only show associations, not cause and effect. Adropin levels may not reliably predict vessel problems, and the findings may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include adult obese participants who are referred to the Sleep Medicine/Chest outpatient clinic with suspected obstructive sleep apnea. Participants will undergo clinical assessment and overnight polysomnography (PSG) to confirm the diagnosis of OSA and determine its severity according to the apnea-hypopnea index (AHI). Participants will be categorized into appropriate study groups according to the presence and severity of OSA. A suitable comparison group of obese participants without OSA may also be included, according to the study design. The study population will include both males and females who meet the predefined inclusion criteria and provide informed consent to participate in the study

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1- Adults aged 20-75 years. 2-obese Patients diagnosed with obstructive sleep apnea (OSA) confirmed by polysomnography. 3- Patients willing to provide written informed consent. 4- Patients not currently on medications affecting endothelial function (e.g., statins, ACE inhibitors) or able to temporarily withhold under medical supervision. 5- Ability to comply with study procedures and follow-up Exclusion Criteria: * 1-Pregnant females 2-Thyroid disorders 3-Autoimmune diseases 4-chronic liver disease 5-chronic kidney disease 6-drugs as statin,glucocorticoids and antidepressant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adropin in patients of OSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adropin in patients of OSA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.